Torsdag 21 Maj | 16:51:45 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-25 08:10 Bokslutskommuniké 2026
2026-11-26 08:10 Kvartalsrapport 2026-Q3
2026-08-27 08:10 Kvartalsrapport 2026-Q2
2026-05-29 N/A X-dag ordinarie utdelning NICA 0.00 SEK
2026-05-21 N/A Årsstämma
2026-05-20 - Kvartalsrapport 2026-Q1
2026-03-04 - Extra Bolagsstämma 2026
2026-02-26 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-07-10 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning NICA 0.00 SEK
2025-05-22 - Årsstämma
2025-04-16 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-09-23 - Extra Bolagsstämma 2024
2024-07-05 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning NICA 0.00 SEK
2024-05-16 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-10-27 - Kvartalsrapport 2023-Q3
2023-07-07 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning NICA 0.00 SEK
2023-05-04 - Årsstämma
2023-04-28 - Kvartalsrapport 2023-Q1
2023-02-10 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-09-15 - Extra Bolagsstämma 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning NICA 0.00 SEK
2022-06-02 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-08 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning NICA 0.00 SEK
2021-05-27 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-29 - X-dag ordinarie utdelning NICA 0.00 SEK
2020-05-28 - Årsstämma
2020-02-26 - Extra Bolagsstämma 2020
2020-02-24 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-27 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning NICA 0.00 SEK
2019-05-29 - Årsstämma
2019-05-10 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning NICA 0.00 SEK
2018-05-31 - Årsstämma
2018-04-25 - Kvartalsrapport 2018-Q1
2018-02-23 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-06-02 - X-dag ordinarie utdelning NICA 0.00 SEK
2017-06-01 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-09-12 - Extra Bolagsstämma 2016
2016-08-26 - Kvartalsrapport 2016-Q2
2016-06-01 - X-dag ordinarie utdelning NICA 0.00 SEK
2016-05-31 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-26 - Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Nanologica är ett bolag inom life science tools som utvecklar, tillverkar och säljer avancerade insatsvaror till läkemedelsproducerande företag. Nanologicas silikabaserade produkter är speciellt framtagna för rening av peptidläkemedel, såsom insulin och GLP-1-analoger. Nanologica verkar på en global nischmarknad för läkemedel för behandling av diabetes och obesitas. Nanologica grundades 2004 och har sitt huvudkontor i Södertälje.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-21 15:17:00

Nanologica AB (publ) today May 21, 2026 held its Annual General Meeting in Stockholm, at which the following resolutions were adopted.

Adoption of the income statement and balance sheet, disposition of result
The Annual General Meeting adopted the income statement and balance sheet for the company and the group in accordance with the presented accounting documents and resolved, in accordance with the board's proposal, that the accumulated loss of SEK -50,180,846 shall be carried forward. The decision means that no dividend will be paid for the financial year 2025.

Discharge
The Annual General Meeting discharged the members of the board of directors and the CEO from liability for the financial year 2025.

Board of directors and board fees
The Annual General Meeting resolved on the re-election of Gisela Sitbon, Mattias Bengtsson, Thomas Eldered, Jeremie Trochu and Lena Torlegård and the election of Mark Quick and Erik Haeffler as new members of the board, all for a term of office that extends until the end of the next Annual General Meeting. Thomas Eldered was elected as chairman of the board.
The Annual General Meeting resolved on fees to the board of directors and fees for committee work in accordance with the nomination committee's proposal as follows: SEK 325,000 to the chairman of the board, SEK 190,000 to each of the other board members, SEK 50,000 to the chairman of the audit committee, SEK 30,000 to each of the other members of the audit committee, SEK 25,000 to the chairman of the remuneration committee and SEK 15,000 to each of the other members of the remuneration committee. All board fees were unchanged compared to the previous year.

Auditor and auditors' fees
The Annual General Meeting resolved, in accordance with the nomination committee's proposal, to appoint the registered auditing firm BDO Mälardalen AB as auditor of the company for the period until the end of the next Annual General Meeting. Niclas Nordström will continue as auditor in charge. Fees to the auditor shall be paid in accordance with approved invoices.

Remuneration report for the financial year 2025
The Annual General Meeting resolved to approve the board's remuneration report for the financial year 2025.

Amendment of the articles of association and reduction of share capital
The Annual General Meeting resolved, in accordance with the board's proposal, to amend the articles of association whereby § 4 is amended so that the share capital shall be not less than SEK 5,500,000 and not more than SEK 22,000,000.
The Annual General Meeting resolved, in accordance with the board's proposal, to reduce the company's share capital by SEK 10,191,865.102, without cancellation of shares. The purpose of the reduction is to cover losses.

Authorization for the board of directors to resolve on issues
The Annual General Meeting resolved to authorize the board of directors to resolve on issues in accordance with the board's proposal. The resolution means that the board of directors is authorized, on one or more occasions, for the period until the next Annual General Meeting, to resolve on issues of shares, convertibles and/or warrants. The board of directors shall be able to resolve on issues with or without deviation from the shareholders' preferential rights and with or without provision for non-cash issue and/or set-off or otherwise with conditions. In respect of issues carried out with deviation from the shareholders' preferential rights, the board of directors shall not be able to make a resolution that means that the amount by which the share capital is increased corresponds to more than twenty (20) percent of the total share capital in the company before the issue has been completed.